Myriad Genetics' Stock Drops After Study Shows Niraparib May Not Need CDx | GenomeWeb

NEW YORK (GenomeWeb) – Following publication of a landmark study involving Tesaro's PARP inhibitor niraparib and Myriad Genetics' myChoice HRD test, Myriad's stock tumbled around 12 percent in Monday afternoon trading.

This past weekend, researchers led by Mansoor Mirza of Copenhagen University Hospital in Denmark presented data from the NOVA trial at a European oncology conference, which compared Tesaro's PARP inhibitor niraparib against placebo in 553 patients with recurrent ovarian cancer who had responded to platinum-based chemotherapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.